These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 23072642)
1. Pazopanib: in advanced soft tissue sarcoma. Deeks ED Drugs; 2012 Nov; 72(16):2129-40. PubMed ID: 23072642 [TBL] [Abstract][Full Text] [Related]
2. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. van der Graaf WT; Blay JY; Chawla SP; Kim DW; Bui-Nguyen B; Casali PG; Schöffski P; Aglietta M; Staddon AP; Beppu Y; Le Cesne A; Gelderblom H; Judson IR; Araki N; Ouali M; Marreaud S; Hodge R; Dewji MR; Coens C; Demetri GD; Fletcher CD; Dei Tos AP; Hohenberger P; ; Lancet; 2012 May; 379(9829):1879-86. PubMed ID: 22595799 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131 [TBL] [Abstract][Full Text] [Related]
5. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. Karch A; Koch A; Grünwald V Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325 [TBL] [Abstract][Full Text] [Related]
6. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174 [TBL] [Abstract][Full Text] [Related]
7. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. Penel N; Mir O; Wallet J; Ray-Coquard I; Le Cesne A; Italiano A; Salas S; Delcambre C; Bompas E; Bertucci F; Saada-Bouzid E; Chaigneau L; Chevreau C; Brodowicz T; Decoupigny E; Vanseymortier M; Laroche L; Taieb S; Le Deley MC; Blay JY Eur J Cancer; 2020 Feb; 126():45-55. PubMed ID: 31918233 [TBL] [Abstract][Full Text] [Related]
8. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656 [TBL] [Abstract][Full Text] [Related]
9. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442 [TBL] [Abstract][Full Text] [Related]
10. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286 [TBL] [Abstract][Full Text] [Related]
11. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011 [TBL] [Abstract][Full Text] [Related]
12. Pazopanib in the treatment of soft tissue sarcoma. Schöffski P Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487 [TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966 [TBL] [Abstract][Full Text] [Related]
14. Pazopanib, a new therapy for metastatic soft tissue sarcoma. Verweij J; Sleijfer S Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774 [TBL] [Abstract][Full Text] [Related]
15. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429 [TBL] [Abstract][Full Text] [Related]
16. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427 [TBL] [Abstract][Full Text] [Related]
18. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417 [TBL] [Abstract][Full Text] [Related]
19. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma. Kim SK; Kim JH; Kim SH; Lee YH; Han JW; Baek W; Woo HY; Jeon MK; Kim HS BMC Cancer; 2021 Mar; 21(1):336. PubMed ID: 33789622 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Schulte B; Mohindra N; Milhem M; Attia S; Robinson S; Monga V; Hirbe AC; Oppelt P; Charlson J; Helenowski I; Abbinanti S; Cehic R; Okuno S; Van Tine BA; Agulnik M Br J Cancer; 2021 Aug; 125(4):528-533. PubMed ID: 34050255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]